(Reuters) - More than 40 percent of patients with moderate to severe ulcerative colitis achieved clinical remission from the debilitating condition after a year of taking an experimental drug developed by Japan's Takeda Pharmaceutical Co, according to data from a pivotal late-stage trial. The biologic drug, vedolizumab, met the goals of the Phase III trial with highly statistically significant advantages in rates of remission, clinical response and bowel healing compared with a placebo, researchers said. Of the patients taking part in the year-long maintenance study, 44. ...
Source: news.yahoo.com
No comments:
Post a Comment